Format

Send to

Choose Destination
Chest. 2013 Jul;144(1):226-233. doi: 10.1378/chest.12-0587.

Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.

Author information

1
Department of Medicine, Duke University, Durham, NC. Electronic address: laurie.snyder@dm.duke.edu.
2
Department of Medicine, Duke University, Durham, NC.
3
Department of Pathology, Duke University, Durham, NC.
4
Department of Pediatrics and Medical Genetics Research Institute, Cedars-Sinai Health Systems, Los Angeles, CA.

Abstract

BACKGROUND:

Long-term survival after lung transplant is limited by the development of chronic and progressive airflow obstruction, a condition known as bronchiolitis obliterans syndrome (BOS). While prior studies strongly implicate cellular rejection as a strong risk factor for BOS, less is known about the clinical significance of human leukocyte antigen (HLA) antibodies and donor HLA-specific antibodies in long-term outcomes.

METHODS:

A single-center cohort of 441 lung transplant recipients, spanning a 10-year period, was prospectively screened for HLA antibodies after transplant using flow cytometry-based methods. The prevalence of and predictors for HLA antibodies were determined. The impact of HLA antibodies on survival after transplant and the development of BOS were determined using Cox models.

RESULTS:

Of the 441 recipients, 139 (32%) had detectable antibodies to HLA. Of these 139, 54 (39%) developed antibodies specific to donor HLA. The detection of posttransplant HLA antibodies was associated with BOS (HR, 1.54; P=.04) and death (HR, 1.53; P=.02) in multivariable models. The detection of donor-specific HLA antibodies was associated with death (HR, 2.42; P<.0001). The detection of posttransplant HLA antibodies was associated with pretransplant HLA-antibody detection, platelet transfusions, and the development of BOS and cytomegalovirus pneumonitis.

CONCLUSIONS:

Approximately one-third of lung transplant recipients have detectable HLA antibodies, which are associated with a worse prognosis regarding graft function and patient survival.

PMID:
23328795
PMCID:
PMC3707175
DOI:
10.1378/chest.12-0587
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center